$81 Billion in Drug Discounts. Where Did the Money Go?

In 1992 Congress built a small program called 340B to do one humane thing: let hospitals and clinics that serve the poor buy outpatient drugs at a steep discount, so the savings could stretch to cover more low-income patients. Three decades later that program moved $81.4 billion in discounted medicines in a single year — up nearly 23% from the year before, and roughly twelve times its size in 2010. It is now the second-largest federal drug program in the country, behind only Medicare Part D.

Here is the part nobody designed and almost nobody polices: the law that mandates the discount never required the discount to reach a patient. A covered hospital can buy a drug at the 340B price, bill a commercial insurer or Medicare the full sticker price, and keep the spread — with no obligation to pass a penny to the sick person who took the pill. Multiply that across $81 billion in purchases and the question writes itself, the same question a RealClear-network columnist aimed straight at the new Department of Government Efficiency in 2025: where did the money go?

The answer, assembled from GAO audits, HRSA data, a Senate investigation, and the program’s own numbers, is that a program sold as charity for the poor has become a profit center for large hospital systems, the pharmacy chains they contract with, and the pharmacy-benefit middlemen who sit between them. The discount is real. The charity, increasingly, is not.

• $81.4 billion — in discounted 340B drug purchases in 2024 — up 22.8% over 2023's $66.3 billion, and about 12x the program's 2010 size · Source: Drug Channels, HRSA
• $66.4 billion — the 2024 gap between drugs' list prices and their 340B purchase prices — a rough proxy for the discount dollars in play, much of it kept rather than passed to patients · Source: Drug Channels
• 87% — of all 340B purchases run through hospitals — not the community health centers most associate with safety-net care · Source: Drug Channels
• 5 of 20 — GAO recommendations to fix HRSA's 340B oversight that the agency had actually implemented as of October 2025 — it rejected 6 outright · Source: GAO-26-108784

The mechanics are simple and the loophole is built into them. Drug manufacturers that want their products covered by Medicaid and Medicare Part B must, as a condition, sell those same drugs to “covered entities” — certain hospitals, federally qualified health centers, and specialty clinics — at a deep statutory discount, typically 25% to 50% off and sometimes far more. The original idea, in HRSA’s own framing, was to let those providers “stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.”

But the statute stops at the purchase. It tells the hospital what it pays the manufacturer; it says nothing about what the hospital charges the patient or the insurer. So when a covered hospital dispenses a 340B drug to a commercially insured patient, it can buy at, say, $1,000 and collect $3,000 from the insurer, pocketing the $2,000 “spread.” The Commonwealth Fund, no opponent of the program, describes this plainly: 340B providers are generally “not required to pass the savings on to patients.” That single design gap is the engine of everything that follows.

Keep Reading

Society · Title IX

A Washington Family Sues Over a Girls' Wrestling Match. The State's Policy Is on Trial.

Read →

A program this lucrative did not stay small. By the analysis of pharmaceutical economist Adam J. Fein of Drug Channels — whose annual tally is the most-cited figure in the field — discounted 340B purchases hit $81.4 billion in 2024, a 22.8% jump over the $66.3 billion recorded for 2023, which itself was up 23.4% over 2022. The Congressional Budget Office traces the same arc from a different angle: from about $6.6 billion in 2010 to $43.9 billion in 2021 and onward. By 2024 the program was moving more than 50% more in drugs than Medicaid’s entire net prescription spend.

Two facts inside the growth reframe the “safety net” label. First, hospitals — not community clinics — account for roughly 87% of all 340B purchases, and disproportionate-share hospitals alone bought nearly $52 billion of the 2023 total. Second, the number of covered-entity sites more than doubled between 2013 and 2023; today there are more than 50,000 340B sites, representing more than 40% of all U.S. hospitals. Researchers have repeatedly found hospitals expanding 340B-eligible clinics into wealthier neighborhoods — where the commercially insured patients, and the fattest spreads, actually are.

“A growing share of 340B dollars are captured by for-profit pharmacies and PBMs.”

Adam J. Fein, Ph.D. · Drug Channels Institute

The clearest map of where the money goes came from the Senate. A multi-year investigation by Sen. Bill Cassidy (R-LA), chair of the Health, Education, Labor and Pensions Committee, documented hospital systems generating enormous 340B revenue with little reaching patients. Richmond Community Hospital, part of Bon Secours Mercy Health, brought in roughly $276.5 million in 340B revenue between 2018 and 2023 while, the report found, it did not pass those savings to patients. The Cleveland Clinic pulled in nearly $933.7 million over three years. More than half of the 340B hospitals Cassidy’s committee surveyed reported that they did not share the discounts with patients at all.

Then there are the middlemen. As contract-pharmacy arrangements exploded — the number of pharmacy contracts rose from about 4,400 in 2010 to more than 75,000 by 2022, most run by Walgreens or CVS — for-profit chains and pharmacy-benefit managers began harvesting the spread directly. Cassidy’s investigation found that roughly 50 cents of every dollar of contract-pharmacy 340B profit flowed to just four large PBM-and-pharmacy companies. CVS’s in-house administrator, Wellpartner, alone collected an estimated $382 million in third-party-administrator fees in 2023; CVS’s specialty pharmacy was found to earn around 13% of negotiated commercial reimbursement on 340B prescriptions. In one illustrative specialty case, Drug Channels calculated a health system could net about $2,429 per prescription — without ever physically dispensing the drug.

Keep Reading

Society · Education

$400,000 for Consultants. A Reading Score That Went Backward. This Is San Francisco Schools.

Read →

If $81 billion is flowing through a federal program, someone is auditing it — lightly. The Government Accountability Office has spent years cataloging the weaknesses at the Health Resources and Services Administration, the small HHS office that runs 340B. In its October 2025 report (GAO-26-108784), the watchdog found HRSA’s audit-closure process “does not ensure covered entities have fully addressed any noncompliance,” that its audits do not adequately check for prohibited “duplicate discounts” — where a drug gets both the 340B price and a Medicaid rebate — and that it fails to verify hospital eligibility before letting entities into the program.

The scoreboard on fixes is the tell. GAO has made 20 recommendations to HRSA; as of October 2025, the agency had implemented just 5. It rejected 6 outright and, on 9 others, agreed in principle while insisting it lacks the statutory authority to act — and asked Congress for more power. HRSA audits roughly 200 covered entities a year out of more than 50,000 sites. Put differently: a program that grew to $81 billion is policed by an office that, on its own account, cannot fully enforce its own rules and reviews well under 1% of participants annually.

So, to the question on the page: where did the money go? The honest answer is that no single ledger tracks it, and that is itself the scandal. HRSA does not require covered entities to report how they spend 340B proceeds. Studies and the Senate investigation point to the same destinations — general operating budgets, capital projects, expansion into affluent markets, executive compensation, and the fees skimmed by contract pharmacies and PBMs — but because the program demands no accounting for “community benefit,” the public cannot follow the bulk of the dollars even if it wanted to.

What can be said with confidence is what the money largely did not do: it did not, in most cases, lower the price the low-income patient paid at the pharmacy counter. The 2018 GAO review of contract pharmacies found that fewer than half of covered entities studied passed the 340B discount on to uninsured patients at those pharmacies. The program is now nearly one-fifth of the entire U.S. “gross-to-net” gap between drug list prices and what is actually paid — a $356 billion distortion in 2024 — and a rising share of it lands in for-profit hands rather than in patient relief.

340B sits in an unusual political spot: the loudest critics include Republicans like Bill Cassidy (R-LA)and free-market policy shops, but the program’s biggest defenders are large hospital lobbies that span both parties, and the prior administration’s HRSA fought drug-makers’ attempts to demand more data — threatening to expel manufacturers who tried to verify eligibility before granting discounts. Reformers want three things that the receipts plainly support: a requirement that savings reach patients, real reporting on how proceeds are spent, and oversight with teeth. The Inflation Reduction Act’s drug-price provisions, analysts note, may also shrink the 340B margin and force some of the transparency the program has resisted for thirty years.

None of this means 340B should not exist. Genuine safety-net hospitals and community health centers do use the discount the way Congress intended, and they would be the first hurt by a clumsy repeal. But a program that has grown to $81 billion a year, sends 87 cents of every purchasing dollar through hospitals rather than clinics, lets middlemen skim half the contract-pharmacy profit, and cannot tell the public where the money went — that program is no longer the thing its name promises. The discount was supposed to buy medicine for the poor. The country deserves to know how much of it still does.

“The 340B program is structurally flawed and vulnerable to abuse by for-profit interests.”

Adam J. Fein, Ph.D. · Drug Channels Institute

More From Civic Intelligence

Society · Accountability

They Raised $634,000 for His Defense. Then He Told the Court He's Penniless.

Karmelo Anthony was convicted of murdering Austin Metcalf and sentenced to 35 years. His family…

Drain the Swamp · Texas

The Lawmaker Who Sat on the Public Education Committee — and Sold DEI to the Schools He Oversaw

Texas state Rep. James Talarico (D-TX), now the Democratic U.S. Senate nominee, spent years as a…

Last updated June 11, 2026